anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a Chinese herbal medicine oral liquid preparation or a herbal tea beverage preparation used for treating rheumatic lumbago-leg pain of a patient that suffers from the disease new. The Chinese herbal medicine oral liquid preparation or the herbal tea beverage preparation is composed of ten Chinese herbal medicines such as Fructus Rosae Laevigatae root, Melastoma dodecandrum Lour, Root, Semiliquidambar, Flemingia philippinensis Merr.et Rolfe, Chloranthvs Holostegius, etc. The special effect oral liquid preparation or the herbal tea beverage preparation is used for preventing and treating the rheumatic lumbago-leg pain, more particularly used for treating the rheumatic lumbago-leg pain disease caused by the exogenous pathogenic factors and the symptoms such as the gall on bones and muscles of vital Qi weakness, Qi blood stasis, fever, aversion to cold, etc.; the invention has the advantages and effects that the preparation of drug material is easy, the raw ingredients are rich, the medicine taking is convenient, the target is accurate, the guidance force is strong, the course of treatment is short, the curative effect is good, any toxic and side effects do not exist, the total effective rate of clinical application for symptomatic treatment is 100 percent, etc.; more particularly, the invention is the innovation to the application technique in domestic international medical field at present, the traditional Chinese herbal medicine oral liquid preparation and the herbal tea beverage preparation are researched and developed so as to fill in a gap on the subject field of new technique and new herbs for the medical treatment of the rheumatic lumbago-leg pain disease, which is a great development on the treatment medicine tea culture research for treating the rheumatic lumbago-leg pain. The Chinese herbal medicine oral liquid preparation or the herbal tea beverage preparation has broad  value of use in the clinical application.
Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
Life- and graft-threatening complications in solid organ transplant patients have been greatly reduced due to the potent immunosuppressive agents like calcineurin inhibitors (CNI) that include cyclosporine and tacrolimus. Venous thromboembolism (clots in legs or lungs) in transplant recipients is often difficult to manage due to polypharmacy and potential for drug interactions. More than 90% of renal transplant (RT) recipients are maintained on a CNI-based immunosuppressive regimen. Cyclosporine is an inhibitor of many metabolic pathways including cytochrome P450 (CYP) 3A4, permeability glycoprotein (P-gp) and, breast cancer resistance protein (BCRP). Tacrolimus shares some of the distributive and metabolic pathways of cyclosporine. Apixaban is a combined substrate of CYP3A4, P-gp and, BCRP and thus has the potential for drug interactions with cyclosporine and tacrolimus. Apixaban levels that are too high or too low could be a problem for transplant patients. The purpose of this study is to determine what happens to apixaban blood levels when given in combination with cyclosporine or tacrolimus.
Isoproterenol is a direct acting Beta-1 and Beta-2 agonist useful for its effects on bronchodilation and myocardial contractility. Its CNS side effects include nervousness, headache, dizziness, restlessness, insomnia, anxiety, tension, blurring of vision, fear, and excitement. In addition to our preliminary data, two case reports show an increase in BIS with administration of isoproterenol. Our hypothesis is that administration of isoproterenol will increase the level of consciousness of the patient as reflected in the BIS reading.

The BIS Vista Monitor is a non-invasive device that measures the electrical activity of the brain. It computes a number between 0 and 100 which corresponds to a level of consciousness which is known as the Bispectral (BIS) value. Using the BIS value to guide administration of anesthetic medication, clinicians can make informed decisions for optimal anesthesia. This technology has the potential to prevent over sedation, but is currently not a standard monitoring device.

Another approach to evaluating the level of consciousness of anesthetized patients is to assess their ability to form memories or recall events which occurred while under anesthesia. Conscious recall is the first to disappear with decreasing levels of consciousness. A BIS of 60 or less has been shown in various studies to be sufficient to prevent conscious recall in the vast majority of patients. We propose to use a modified isolated forearm technique test in which the patient is asked to squeeze an observer's hand during anesthesia to ascertain if awareness can occur without recall at a BIS of 60 to 70. (6) Implicit memory in which there is no conscious recall or evaluation of awareness can be assessed by word stem completion tests and has been shown to occur with a BIS as low as 40 - 60 although these results are not consistent across all studies. (7)
Hydrochlorothiazide is a diuretic and antihypertensive agent. It blocks the renal tubular absorption of sodium and chloride ions. This natriuresis and diuresis is accompanied by a secondary loss of potassium and bicarbonate. Onset of hydrochlorothiazide’s diuretic effect occurs within 2 hours and the peak action takes place in 4 hours. Diuretic activity persists for approximately 6 to 12 hours.

The exact mechanism of hydrochlorothiazide’s antihypertensive action is not known, although it may relate to the excretion and redistribution of body sodium. Hydrochlorothiazide does not affect normal blood pressure. Following oral administration, peak hydrochlorothiazide plasma levels are attained in approximately 2 hours. It is excreted rapidly and unchanged in the urine.

Well-controlled studies have demonstrated that doses of hydrochlorothiazide as low as 25 mg given once daily are effective in treating hypertension, but the dose-response has not been clearly established.
Participants will be randomized into groups A and B. When the subject's group cohort undergoes the intervention phase (as opposed to the control phase), they will receive a 7-day, 8-hour intervention with an electric blanket set at +5±1°C above room temperature.
FIELD: medicine. 
     SUBSTANCE: invention refers to medicine, namely rheumatology, balneotherapy and physiotherapy. The method involves the integrated treatment. There are prescribed sulphide bath with the total hydrogen sulphide concentration of 158 mg/l, the free hydrogen sulphide concentration of 108 mg/l at temperature 36-37°C. The length of the first 2-3 baths is 6-8 minutes. The length is to be increased to 8-12 minutes. The baths are taken within the period of 10.00 to 12.00 every second day. The therapeutic course is 10-12 procedures. On the same days, within the period of 14.00 to 16.00, therapeutic exercises are done, and the climatic and landscape therapy is prescribed. On the days free from taking baths, within the period of 10.00 to 12.00, the EHF therapy is prescribed to cover biologically active points (BAP) at frequency 40-43 GHz. The points G-41, 3E-5 are exposed. The hip osteoarthrosis requires the exposure on the points G-29, G-30. If observing the upper extremity osteoarthrosis, the points 3E-4, Du-4, Du-5, Di-5 are covered. In case of the knee osteoarthrosis, the points M-34, M-35, Le-7, Le-8 are exposed. The length of the exposure covering one BAP makes 5-6 minutes. The total length of the procedure is 20-30 minutes. On the same days within the period of 14.00 to 16.00, high-mineralised average sulphide mud is applied at temperature 38-40°C on the involved joints and respective spinal reflexogenic zones. A single procedure covers not more than 2-3 greater joints. The length of one procedure is 20-25 minutes. The therapeutic course is 8-10 procedures. The total length of the rehabilitation makes 20-24 days. 
     EFFECT: method prolongs the remission. 
     2 tbl, 1 dwg, 1 ex
1339256 Bleaching oils and fats HENKEL & CIE GmbH 30 July 1971 [31 July 1970] 35853/71 Heading C5C [Also in Divisions A5-A6 D1-D2 and C6-C7] Oils, fats and waxes are bleached using a peroxy-compound activated by the addition of a 1,4-diacylated 2,5-diketopiperazine activator having the Formula I in which R 1  and R 2  are preferably the same and each represent a hydrocarbon group having 1 to 8 carbons which may be substituted and  R 3  and R 4  are preferably the same and each represent a hydrocarbon group having 1 to 3 carbons which may be substituted. Preferred groups R 1 , R 2  are methyl ethyl, n- or isopropyl, phenyl, tolyl or xylyl residues, optionally substituted by C 1-3  alkoxy, halogen, nitro, or cyano groups. Preferred groups R 3 , R 4  are methyl or ethyl residues, optionally substituted by hydroxyl, halogen, nitro, cyano, methoxy or ethoxy groups. Specified peroxy-compounds include hydrogen peroxide, addition products of hydrogen peroxide and urea or melamine, peroxyhydrates such as perborates, percarbonates, persilicates and perortho-, perpyro- and perpoly-phosphates, and salts of peroxymono- or peroxydisulphuric acid. The activator and peroxy compound may be formulated as a bleaching and/or oxidizing liquid, which may also contain anionic, cationic, non- ionic or amphoteric detergents, alkaline substances and complex forming substances for binding water hardening substances and heavy metal ions. The liquid preferably has a ratio of 0À5-6 acyl residues per active oxygen atom, and may be used at a pH from 7-13. Bleaching may be effected at ambient or elevated temperatures, or in two stages at different temperatures. Examples describe the activation of perborate in the presence of sodium pyrophosphate with 1,4-diacetyl-2,5-diketo piperazine, 1,4-dipropionyl-2,5-diketo piperazine or 3,6-dimethyl-1,4-diacetyl-2,5-diketo piperazine, and the activation of hydrogen peroxide with the first two activators.
BACKGROUND: Consultation-liaison (CL) psychiatrists are frequently asked to consult on various abnormal movements (1). CL psychiatrists can be instrumental in aiding the primary teams to identify and manage these movement disorders. In this manuscript, we provide an illustrative case of a patient presenting with myoclonus and offer a review on this important topic. Myoclonus accompanied by delirium represents a rare post-transplant complication and can be associated with heightened morbidity and mortality. The incidence of this complication in solid organ transplant recipients is scarcely documented, and its pathophysiology remains inadequately understood. Potential etiologies in the intensive care unit are numerous and likely multifactorial. The literature lacks detailed descriptions of the correlation and association between myoclonus and uremia. Management of this condition requires a multimodal approach, focusing on resolving underlying metabolic disturbances and providing symptomatic treatment.
OBJECTIVE: This manuscript describes the clinical presentation of myoclonus in a liver transplant recipient accompanied by delirium and precipitated by uremia. We aim to highlight the diagnostic and therapeutic complexities, help providers distinguish myoclonus from other movement disorders, and aid appropriate management.
METHODS AND RESULTS: We present a case of acute myoclonus in an elderly female liver transplant recipient precipitated by uremia and improved after continuous renal replacement treatment. In addition, we conducted a systematic review utilizing EMBASSE and PubMed of reported cases of myoclonus, delirium, and/or encephalopathy accompanied by uremia. We included 12 manuscripts in our review and discussed their findings.
CONCLUSIONS: CL psychiatrists are frequently consulted for a range of movement disorders in the intensive care unit, including myoclonus. Accurate diagnosis and identification of contributing etiologies are critical in these cases. Management typically involves addressing the underlying disorder, such as using dialysis for uremia, alongside symptomatic treatment with benzodiazepines to mitigate the frequency and amplitude of myoclonus. This approach helps to alleviate both the physical burden and psychological distress associated with the condition. This case underscores the pivotal role of the CL psychiatrist within a complex multidisciplinary team, contributing to diagnostic precision and optimization of management strategies for movement disorders.
Despite the fact that HAART produces a decrease in HIV-1 replication and plasma HIV-1 RNA levels, and allows an increase in the CD4 T-cell count that leads to a diminution in the incidence of opportunistic infections and mortality, the cost and complexity of HAART regimens, the growing list of long-term side effects, and the eventual development of resistance have underscored the immediate need for additional therapeutic approaches. Statins exert pleiotropic effects through a variety of mechanisms, among which there are several immunological effects that are related and unrelated to their cholesterol-lowering activity. HIV-1 requires cholesterol and lipid rafts for several key stages of its replication cycle; statins-mediated depletion of cholesterol alters the capacity of a cell to form lipid rafts and decreases the HIV-1 infectivity. On the other hand, statins may exert significant modulator effects in the balance of the cytokine network, and alter the activity of Rho GTPases and LFA-1 and ICAM-1 adhesion molecules. Preliminary studies showed that statins (Lovastatin) had anti HIV-1 activity, and that its administration was safe and efficient to control HIV-1 infection in chronically infected individuals who did not receive HAART (in terms of decreasing viral load and increasing CD4 T-cell count). Because very limited clinical data are available on this topic, this study will be conducted.
Strict aseptic technique must always be maintained during handling. Propofol injectable emulsion is a single-dose parenteral product (single patient infusion vial) which contains benzyl alcohol to inhibit the rate of growth of microorganisms, for up to 12 hours, in the event of accidental extrinsic contamination. However, propofol injectable emulsion can still support the growth of microorganisms, as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits. There have been reports in which failure to use aseptic technique when handling propofol injectable emulsion was associated with microbial contamination of the product and with fever, infection/sepsis, other life-threatening illness, and/or death.

Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person.

There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and of the use of propofol vials intended for single use on multiple persons.
The invention belongs to the technical field of cosmetics, and particularly relates to acne treatment essence cream and a preparing method thereof. The essence cream contains aluminum starch octenylsuccinate, salicylic acid, PCA zinc, zinc gluconate, nicotinamide, tangerine orange pericarp extract, amur corktree bark extract and retinyl palmitate. The acne treatment constituents in the essence cream are obtained through screening. The new acne treatment constituents in the essence cream can effectively restrain propionibacterium acnes. Experimental studies prove that a good acne treatment effect can be realized by adding the acne treatment constituents to the essence cream. Stability studies show that the essence cream has higher stability.
Clinical trials of LIALDA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of blood dyscrasias (i.e., agranulocytosis, neutropenia, and pancytopenia) in patients who were 65 years or older who were taking mesalamine-containing products such as LIALDA compared to younger patients. Monitor complete blood cell counts and platelet counts in elderly patients during treatment with LIALDA.

Systemic exposures are increased in elderly subjects [see Clinical Pharmacology (12.3)].

In general, consider the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients when prescribing LIALDA. Consider starting at the low end of the dosing range for induction in elderly patients [see Dosage and Administration (2), Use in Specific Populations (8.6)].
The invention provides a rapid screening system for cognitive impairment of old people, which comprises an eye movement tracking device, a balancing instrument and a screening server. A gaze target unit of the eye tracking device is used for presenting a target for gaze in the center of the screen; the target stimulation unit is used for providing stimulation to enable the fixation target unit to appear, disappear or move; the eye movement information acquisition unit is used for acquiring eye position changes when the eyes appear, disappear or move along with the gazing target unit. And the pressure sensor of the balancing instrument is used for acquiring the pressure value borne by the balancing plate. The screening server comprises an eye movement track calculation unit, a balance gravity center calculation unit and a judgment unit. The eye movement trajectory calculation unit calculates the eye jump number and/or the eye jump delay time based on the eye position change. The balance center of gravity calculation unit calculates a balance center of gravity displacement and a balance center of gravity offset based on the pressure value. The determination unit obtains the screening result based on the eye jump number and/or the eye jump delay time, and/or the balance center of gravity displacement and/or the balance center of gravity shift.
Several studies have established an association between the blood group type and susceptibility to infections. This study aimed to evaluate a correlation between the blood group type and the susceptibility to infection. A total of 558 patients were enrolled in this study who attended at the Althawra Hospital, Ibb City, from March to August 2018. Blood samples were analyzed for complete blood count and blood group. We observed a high frequency of infections affecting the digestive system (26.4%), while the least affected system was the urogenital system 5.9%. Patients with A blood group exhibit an increased probability to be infected by viruses than they do for bacteria (odds ratio [OR] = 1.430; 95% confidence interval [CI] = 1.005 to 2.035; P = 0.05 and OR = 0.098; 95% CI = 0.064 to 0.148; P < 0.0001, respectively). It was observed that blood group A individuals were more susceptible to infection with hepatitis B virus than were the other groups (P = 0.041; OR = 1.704, 95% CI = 1.053-2.773). The liklihood of O blood group patients experiencing urogenital infections was less than that of non-O blood group patients one third (OR = 0.353, 95% CI = 0.158-0.789; P = 0.014). This study corroborates previous findings that demonstrated that certain blood groups are more prone to infection by one agent than are patients with other blood groups.
Cannabis is by far the most frequently used illicit drug worldwide and has significant effects on memory. Further, cannabis has an addictive potential. These effects are mediated by an action of THC, the main psychoactive ingredient of cannabis, on cannabinoid CB1 receptors. These receptors are particularly highly expressed in brain regions involved in memory and reward. Therefore, in this study we will investigate the acute effects of THC on functional brain systems underlying memory and reward. We will visualize these effects using the latest non-invasive imaging technique: pharmacological MRI (phMRI).
Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
FIELD: medicine. SUBSTANCE: method deals with treating infectious diseases, relapsing herpes among them. Thus, during exacerbation period one should prescribe the combination of valtrex along with polyoxydonium, neovir and derinate preparations. When relapse therapy is over cycloferon is prescribed in combination with alpyzarin, group B-vitamins and "Moskoviya" balm-biostimulator. The method provides complex impact both onto disease's agent and body immune system. EFFECT: higher efficiency of therapy.
Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
Diseases of the memory, including dementia and Alzheimer's disease, are a primary health concern of the aging population. In just the last 30 years, the number of Americans diagnosed with memory diseases has doubled. The beginning signs and symptoms of Alzheimer's and dementia include mild forgetfulness, confusion, and disorientation with time and place. As the diseases advance, people often experience difficulty in carrying out normal activities, recognizing family and friends, and eventually speaking and comprehending. Early identification and treatment for dementia and Alzheimer's may help prevent and slow the progression of symptoms, but the most beneficial means of treatment is still unknown. Previous studies have suggested a link between menopause and reduced memory function in women, possibly attributed to the dramatic decline in the levels of the female hormones estrogen and progesterone. HRT in postmenopausal women may help to curb memory loss and reduce risk of developing memory-related diseases. This study will evaluate the effects of female HRT on the development and progression of memory loss in older women enrolled in the WHI study.

Participants in this study will be drawn from the WHI study and will have previously been assigned to HRT with estrogen, HRT with estrogen plus progesterone, or placebo. During this study, participants will continue to take their assigned treatments from the WHI study.

Participation will last up to 6 years. All participants will undergo baseline memory and thinking tests, including a mood assessment and tasks measuring memory and other brain functions. Study staff will conduct a telephone interview with a close family member or friend. Some participants may additionally undergo a 45-minute interview with a clinician, a blood draw, and a computerized tomography (CT) scan. All participants will repeat the baseline memory and thinking tests once annually for 6 years, and some participants will repeat the interview, blood draw, and CT scan at these annual visits as well.
The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.